|Table of Contents|

Construction of mouse melanoma models based on PD-L1/TIL

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 23
Page:
4318-4325
Research Field:
Publishing date:

Info

Title:
Construction of mouse melanoma models based on PD-L1/TIL
Author(s):
WU Zhanshuai
Guangxi University of Chinese Medicine,Guangxi Nanning 530200,China.
Keywords:
melanoma; PD-L1; TIL; H-2Kb
PACS:
R739.5
DOI:
10.3969/j.issn.1672-4992.2023.23.005
Abstract:
Objective:To construct PD-L1+/TIL+ and PD-L1+/TIL- mouse melanoma models consistent with clinical characteristics based on programmed cell death ligand 1(PD-L1) and tumor infiltrating lymphocytes(TIL).Methods:The H-2Kb+ cell lines,encoded by major histocompatibility complex class I gene,were screened from H-2Kb- mouse melanoma cell B16 by flow cytometry.The growth rate,tumor formation rate,cytokine secretion,T lymphocyte infiltration and PD-L1 expression of these cell lines were investigated through animal experiment,immunohistochemistry and flow cytometry,and so on.Results:Eight H-2Kb+ cell lines were selected,among which 2F10 and 2G1 cell lines had sustained and stable expression of H-2Kb.They had slow growth rate and slow tumorigenation and secreted MCP-1 and IL-6.T lymphocytes infiltration could be detected after 2F10 tumor formation and PD-L1 expression could be detected in both cells and tumor tissues.Conclusion:PD-L1+/TIL+ and PD-L1+/TIL- mouse melanoma models conforming to clinical characteristics were constructed using H-2Kb+ cell lines.

References:

［1］ZENG LL,GOWDA BHJ,AHMED MG,et al.Advancements in nanoparticle-based treatment approaches for skin cancer therapy［J］.Mol Cancer,2023,22:10.
［2］CHESNEY J,LEWIS KD,KLUGER H,et al.Efficacy and safety of lifileucel,a one-time autologous tumor-infiltrating lymphocyte(TIL) cell therapy,in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies:Pooled analysis of consecutive cohorts of the C-144-01 study［J/OL］.J Immunother Cancer,2022,10(12)［2022-12-3］.https://jitc.bmj.com/content/10/12/e005755.DOI:10.1136/jitc-2022-005755.
［3］SIEGEL RL,MILLER KD,WAGLE NS,et al.Cancer statistics,2023［J］.CA Cancer J Clin,2023,73(1):17-48.
［4］ZHENG R,ZHANG S,ZENG H,et al.Cancer incidence and mortality in China,2016［J］.J Nat Cancer Cent,2022,2(1):1-9.
［5］ROSENBERG SA,SPIESS P,LAFRENIERE R.A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphp-cytes［J］.Science,1986,233(4770):1318-1319.
［6］ZACHARAKIS N,CHINNASAMY H,BLACK M,et al.Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer［J］.Nat Med,2018,24(6):724-730.
［7］CREELAN BC,WANG C,TEER JK,et al.Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer:A phase 1 trial［J］.Nat Med,2021,27:1410-1418.
［8］DENIGER DC,PASETTO A,ROBBINS PF,et al.T-cell responses to TP53 "Hotspot" mutations and unique neoantigens expressed by human ovarian cancers［J］.Clin Cancer Res,2018,24:5562-5573.
［9］ZHAO Y,DENG J,RAO S,et al.Tumor infiltrating lymphocyte(TIL) therapy for solid tumor treatment:Progressions and challenges［J］.Cancers(Basel),2022,14(17):4160.
［10］PAUL S,CROFT NP,PURCELL AW,et al.Benchmarking predictions of MHC class I restricted T cell epitopes in a comprehensively studied model system［J/OL］.PLoS Comput Biol,2020,16(5)［2022-12-10］.https://pubmed.ncbi.nlm.nih.gov/32453790/.DOI:10.1371/journal.pcbi.1007757.
［11］WU Y,ZHAI W,ZHOU X,et al.HLA-A2-restricted epitopes identified from MTA1 could elicit antigen-specific cytotoxic T lymphocyte response［J/OL］.J Immunol Res,2018［2023-01-31］.https://pubmed.ncbi.nlm.nih.gov/30596107/.DOI:10.1155/2018/2942679.
［12］TAUBE JM,ANDERS RA,YOUNG GD,et al.Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape［J］.Sci Transl Med,2012,4(127):127-137.
［13］KIM TK,VANDSEMB EN,HERBST RS,et al.Adaptive immune resistance at the tumour site:Mechanisms and therapeutic opportunities［J］.Nat Rev Drug Discov,2022,21(7):529-540.
［14］WANG YL,GAO MH,LI XY,et al.Structural analyses of a dominant cryptosporidium parvum epitope presented by H-2Kb offer new options to combat cryptosporidiosis［J/OL］.mBio,2023［2023-05-30］.https://pubmed.ncbi.nlm.nih.gov/36602309/.DOI:10.1128/mbio.02666-22.
［15］ZOLKIND P,PRZYBYLSKI D,MARJANOVIC N,et al.Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma［J］.Oncotarget,2017,9(3):4109-4119.
［16］LI M,XU F,MULLER J,et al.Loss of retrovirus production in JB/RH melanoma cells transfected with H-2Kb and TAP-1 genes［J］.Virology,1999,253(2):230-240.
［17］MULLER J,KHAN AS,LI M,et al.Phenotypic changes and loss of melanoma-specific endogenous c-type retroviruses in BL6 melanoma cells transfected with the H-2Kb gene［J］.Melanoma Res,1996,6(2):101-111.
［18］DE GIOVANNI C,NICOLETTI G,SENSI M,et al.H-2Kb and H-2Db gene transfections in B16 melanoma differently affect non-immunological properties relevant to the metastatic process.Involvement of integrin molecules［J］.Int J Cancer,1994,59(2):269-274.
［19］ITOH T,STORKUS WJ,GORELIK E,et al.Partial purification of murine tumor-associated peptide epitopes common to histologically distinct tumors,melanoma and sarcoma,that are presented by H-2Kb molecules and recognized by CD8+ tumor-infiltrating lymphocytes［J］.J Immunol,1994,153(3):1202-1215.
［20］KIM M,HERBERMAN R,GORELIK E.Evidence for indirect involvement of the H-2Kb gene in the regulation of natural killer sensitivity of BL6 melanoma cells［J］.Nat Immun,1994,13(1):1-14.
［21］NAKASONE Y,FUJIMOTO M,MATSUSHITA T,et al.Host-derived MCP-1 and MIP-1α regulate protective anti-tumor immunity to localized and metastatic B16 melanoma［J］.Am J Pathol,2012,180(1):365-374.
［22］TANG MR,WANG YX,HAN SH,et al.Endogenous PGE2 induces MCP-1 expression via EP4/p38 MAPK signaling in melanoma［J］.Oncol Lett,2013,5(2):645-650.
［23］KOGA M,KAI H,EGAMI K,et al.Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice［J］.Biochem Biophys Res Commun,2008,365(2):279-284.
［24］MYAKOSHINA EB,KULIKOVA IG,BALATSKAYA NV,et al.The role of CXC and CC chemokines in patients with uveal melanoma［J］.Vestn Oftalmol,2021,137(4):31-37.
［25］OZBEK S,PETERS M,BREUHAHN K,et al.The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells［J］.Oncogene,2001,20(8):972-979.
［26］MIRJACIC MARTINOVIC K,VULETIC A,TISMA MILETIC N,et al.Increased circulating monocyte MDSCs positively correlate with serum interleukin-10 in metastatic melanoma patients［J］.Innate Immun,2023,29:37-44.
［27］WEBER R,RIESTER Z,HUSER L,et al.IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma［J/OL］.J Immunother Cancer,2020,8(2)［2023-01-31］.https://pubmed.ncbi.nlm.nih.gov/32788238/.DOI:10.1136/jitc-2020-000949.
［28］TOBIN RP,JORDAN KR,KAPOOR P,et al.IL-6 and IL-8 are linked with myeloid-derived suppressor cell accumulation and correlate with poor clinical outcomes in melanoma patients［J］.Front Oncol,2019,9:1223.
［29］JOBE NP,ROSEL D,DVORANKOVA B,et al.Simultaneous blocking of IL-6 and IL-8 is sufficient to fully inhibit CAF-induced human melanoma cell invasiveness［J］.Histochem Cell Biol,2016,146(2):205-217.
［30］ZHOU JG,LIANG R,WANG HT,et al.Identification and characterization of circular RNAs as novel putative biomarkers to predict anti-PD-1 monotherapy response in metastatic melanoma patients-Knowledge from two independent international studies［J/OL］.Neoplasia,2023［2023-05-30］.https://pubmed.ncbi.nlm.nih.gov/36696838/.DOI:10.1016/j.neo.2023.100877.
［31］OLSON D,LUKE J.A plain language summary from pembrolizumab plus ipilimumab following PD-1 antibody failure in melanoma［J］.Future Oncol,2022,18(20):2483-2487.
［32］VANELLA V,FESTINO L,VITALE MG,et al.Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma［J］.Expert Opin Emerg Drugs,2021,26(2):79-92.
［33］WILLSMORE ZN,COUMBE BGT,CRESCIOLI S,et al.Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade:Treatment of melanoma and immune mechanisms of action［J］.Eur J Immunol,2021,51(3):544-556.
［34］TROJANIELLO C,VITALE MG,ASCIERTO PA.Triplet combination of BRAF,MEK and PD-1/PD-L1 blockade in melanoma:The more the better［J］.Curr Opin Oncol,2021,33(2):133-138.
［35］WRIGHT Q,GONZALEZ CRUZ JL,WELLS JW,et al.PD-1 and beyond to activate T cells in cutaneous squamous cell cancers:The case for 4-1BB and VISTA antibodies in combination therapy［J］.Cancers(Basel),2021,13(13):3310.
［36］HONG DS,GOPAL AK,SHOUSHTARI AN,et al.Utomilumab in patients with immune checkpoint inhibitor-refractory melanoma and non-small-cell lung cancer［J/OL］.Front Immunol,2022,13［2023-01-31］.https://pubmed.ncbi.nlm.nih.gov/35983060/.DOI:10.3389/fimmu.2022.897991.
［37］HALL MS,MULLINAX JE,COX CA,et al.Combination nivolumab,CD137 agonism,and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma［J］.Clin Cancer Res,2022,28(24):5317-5329.
［38］MELERO I,SANMAMED MF,GLEZ-VAZ J,et al.CD137(4-1BB)-based cancer immunotherapy on its 25th anniversary［J］.Cancer Discov,2023,13(3):552-569.

Memo

Memo:
广西自然科学基金青年科学基金项目（编号：2020GXNSFBA159064）
Last Update: 2023-10-31